BPMC insider trading

Blueprint Medicines Corp — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades
1,058
Last 90 days
0
Buys / sells
0% / 58%
Market cap

BPMC insider activity at a glance

FilingIQ has scored 1,058 insider transactions for BPMC since Nov 10, 2015. The most recent filing in our index is dated Jul 17, 2025.

Across the full history, 3 open-market purchases and 609 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on BPMC insider trades is 61.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

Latest BPMC Form 4 filings

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

13F funds holding BPMC

Frequently asked

How many insider trades does FilingIQ track for BPMC?
FilingIQ tracks 1,058 Form 4 insider transactions for BPMC (Blueprint Medicines Corp), covering filings from Nov 10, 2015 onwards. 0 of those were filed in the last 90 days.
Are BPMC insiders net buyers or net sellers?
Across the full Form 4 history for BPMC, 3 transactions (0%) were open-market purchases and 609 (58%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does BPMC insider data come from?
Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

Methodology & sources

Every BPMC insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.